MK-677 vs Ipamorelin: Oral vs Injectable GH Secretagogue Comparison
MK-677 (Ibutamoren) is an oral non-peptide ghrelin mimetic that provides sustained 24-hour growth hormone and IGF-1 elevation without injections. Ipamorelin is an injectable selective GHRP that produces clean, pulsatile GH release with minimal cortisol, prolactin, or appetite side effects. This comparison covers the key trade-offs between oral convenience and injectable precision for growth hormone research.
Side-by-Side Comparison
| Parameter | MK-677 | Ipamorelin |
|---|---|---|
| Class | Non-peptide ghrelin mimetic (GHS) | GHRP (Growth Hormone Releasing Peptide) |
| Mechanism | Sustained ghrelin/GHS receptor agonism | Selective ghrelin/GHS receptor agonism (pulsatile) |
| Evidence Grade | B+ | B+ |
| Route | Oral (capsule/liquid) | Subcutaneous injection |
| Typical Dose | 10 - 25 mg once daily | 200 - 300 mcg, 2-3x daily |
| Half-Life | ~24 hours | ~2 hours |
| GH Release Pattern | Sustained elevation (24h) | Pulsatile (mimics natural rhythm) |
| IGF-1 Elevation | Significant, sustained increase | Moderate, pulsatile increase |
| Appetite Impact | Significant increase (common) | Minimal |
| Blood Sugar Impact | May increase fasting glucose | Minimal |
| Cortisol Impact | Possible mild increase | Minimal (selective) |
| Water Retention | Common (moderate to significant) | Mild |
| Sleep Quality | Often improves (deep sleep) | May improve when dosed before bed |
| Convenience | High (once-daily oral) | Low (2-3 daily injections) |
| FDA Status | Not approved; investigational | Not approved; research compound |
| Cost (research grade) | $ | $ |
MK-677: Pros & Cons
Advantages
- Oral dosing eliminates injection requirement
- Once-daily dosing with 24-hour half-life
- Sustained GH and IGF-1 elevation around the clock
- Significant improvement in sleep quality
- Well-studied with multiple human clinical trials
- Low cost and widely available
Considerations
- Significant appetite increase (problematic for some)
- May raise fasting blood glucose and insulin resistance
- Notable water retention and bloating
- Non-pulsatile GH release (less physiological)
- Possible cortisol elevation in some individuals
- Long-term safety data limited beyond 2 years
Ipamorelin: Pros & Cons
Advantages
- Cleanest side effect profile among GH secretagogues
- Pulsatile GH release mimics natural physiology
- No significant cortisol or prolactin elevation
- Minimal appetite stimulation
- No impact on blood glucose or insulin sensitivity
- Excellent synergy when combined with GHRH analogs
Considerations
- Requires 2-3 subcutaneous injections daily
- Short half-life (~2 hours) limits duration of effect
- Lower total 24-hour GH elevation than MK-677
- Requires reconstitution and proper storage
- Best results need GHRH analog combination
- Injection compliance can be challenging
Which Is Right for Your Research?
Decision Guide
Choose MK-677 if: Oral convenience is a priority, you want sustained 24-hour GH/IGF-1 elevation, or you are researching sleep quality and appetite effects. MK-677 is ideal for long-term GH optimization studies where injection compliance is a barrier. Be prepared for appetite increase and monitor blood glucose.
Choose Ipamorelin if: You want the cleanest, most selective GH release without metabolic side effects. Ipamorelin is ideal for researchers who prioritize pulsatile, physiological GH patterns and want to avoid appetite stimulation, blood sugar changes, and water retention. Best results come from combining with CJC-1295 or sermorelin.
Key trade-off: MK-677 wins on convenience and sustained IGF-1 elevation. Ipamorelin wins on selectivity, safety profile, and physiological GH patterning. The choice ultimately depends on whether convenience or precision matters more for your research objectives.
Frequently Asked Questions
It depends on priorities. MK-677 offers oral convenience with sustained 24-hour GH/IGF-1 elevation. However, it increases appetite, may elevate blood sugar, and causes water retention. Ipamorelin produces cleaner, selective GH pulses without these side effects but requires multiple daily injections. For clean GH release, ipamorelin is superior. For convenience, MK-677 wins.
Some researchers combine them, though this is less common than ipamorelin + CJC-1295. Since both act through the ghrelin/GHS receptor pathway, combining them may not produce the same synergy as a GHRP + GHRH combination. If combined, lower doses of each are typically used.
Yes. MK-677's sustained ghrelin receptor activation can increase fasting blood glucose by 5-10 mg/dL on average. Ipamorelin's brief, pulsatile GH release does not significantly impact blood sugar or insulin sensitivity, making it the better choice for metabolic-sensitive research.
Related Protocol Guides
Verified Research Suppliers
Research-grade peptides are available from verified suppliers listed on our Vendor Comparison page. All listed vendors meet cGMP certification and third-party testing standards.
Related Tools & Resources
© 2026 Path to Peptides™. For research and educational purposes only. Not medical advice.
Some links on this site may earn a commission at no cost to you.